CAV1 and prostate cancer: Furthermore, elucidation of the mechanistic basis underlying this lipid oncometabolism yields a Cav-1 sphingolipid signature that is detectable in blood and that may be indicative of disease progression in subjects with early stage prostate cancer who are enrolled on active surveillance.